BiomX Inc (AMEX: PHGE)’s stock price has gone rise by 7.78 in comparison to its previous close of 0.39, however, the company has experienced a -4.47% decrease in its stock price over the last five trading days. https://www.marketscreener.com reported 2025-06-09 that Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance Corporate Presentation June 2025 aAdsList.push(‘Article’); aAdsListSize.push([300, 250]); aAdsListCA.push(null); NYSE American: PHGE Opportunity: Clinical stage programs targeting a critical threat to the global healthcare system – antibiotic resistance Phage Therapy Promise Alarming rise in antimicrobial resistance signals urgent need for better treatment Phage therapy emerging as a powerful solution for persistent infections, supported by growing body of efficacy and safety data BX211 – S. aureus infections Positive efficacy and safety data (Phase 2) in DFI & DFO with S. aureus infection, showing sustained ulcer reduction and superior recovery outcomes in bone-depth ulcers Potential additional Phase 2 ready indications: PJI BX004 – P. aeruginosa infections Positive Phase 1b/2a data in CF patients with P. aeruginosa infection, demonstrating sputum culture conversion, improved lung function, and bacterial reduction Phase 2b study ongoing Potential additional Phase 2 ready indications: NCFB, HAP/VAP DFI: Diabetic Foot Infection; DFO: Diabetic Foot Osteomyelitis; PJI: Prosthetic Joint Infection 3 CF: Cystic Fibrosis; NCFB: Non-cystic Fibrosis Bronchiectasis; HAP/HVP: Hospital-acquired / Ventilator-associated Pneumonia Antimicrobial Resistance: Rising concerns and limited treatment options underscore the urgent need for novel therapies 42% 35% 70% >2x Resistance Rate for Cephalosporin-resistant E. coli1 Resistance Rate for Methicillin-resistant S. aureus1 Increase in Death Associated with Antimicrobial Resistance Expected by 20502 Increase in Death Associated with Antibiotic Resistant S. aureus from 1990 to 20212 10M Annual Deaths by 2050 WHO projected Antimicrobial Resistance Mortality3 $100T Drug Resistant Infection Cumulative Economic Loss by 20504 World Health Organization (2022). Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. GBD 2021 Antimicrobial Resistance Collaborators (2024). Lancent. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050 4 World Health Organization. (2019, April 29). New report calls for urgent action to avert antimicrobial resistance crisis O’Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance Phage Therapy: A century-old solution with renewed promise Key Advantages Active against Antibiotic Resistant Strains Safe Modality, Inert to Human Cells, and Supported by FDA No Disruption to Microbiome -Targets Only Harmful Bacteria Penetrates and Disrupts Biofilm Self-Amplifying Phages Increase Efficacy of Each Dose Ability to Launch Straight into Early/Mid Clinical Development Though first discovered >100 years ago, phage therapy struggled to gain traction-now, with rising antibiotic resistance and recent positive clinical data, we believe that its breakthrough moment has finally arrived 5 Attention: This is an excerpt of the original content. To continue reading it, access the original document here. AttachmentsOriginal documentPermalinkDisclaimer BiomX Inc. published this content on June 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 09, 2025 at 14:01 UTC.
Is It Worth Investing in BiomX Inc (AMEX: PHGE) Right Now?
Moreover, the 36-month beta value for PHGE is 1.44. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PHGE is 11.01M and currently, short sellers hold a 0.90% of that float. On June 18, 2025, PHGE’s average trading volume was 135.23K shares.
PHGE’s Market Performance
PHGE stock saw a decrease of -4.47% in the past week, with a monthly decline of -23.88% and a quarterly a decrease of -30.90%. The volatility ratio for the week is 2.23%, and the volatility levels for the last 30 days are 2.70% for BiomX Inc (PHGE). The simple moving average for the last 20 days is -11.20% for PHGE’s stock, with a simple moving average of -41.60% for the last 200 days.
Analysts’ Opinion of PHGE
Many brokerage firms have already submitted their reports for PHGE stocks, with Ladenburg Thalmann repeating the rating for PHGE by listing it as a “Buy.” The predicted price for PHGE in the upcoming period, according to Ladenburg Thalmann is $25 based on the research report published on April 15, 2021 of the previous year 2021.
PHGE Trading at -20.25% from the 50-Day Moving Average
After a stumble in the market that brought PHGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.12% of loss for the given period.
Stock Fundamentals for PHGE
Current profitability levels for the company are sitting at:
- -420.69 for the present operating margin
- -27.64 for the gross margin
The net margin for BiomX Inc stands at -136.65. The total capital return value is set at 5.27. Equity return is now at value -68.18, with -25.38 for asset returns.
Based on BiomX Inc (PHGE), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -3.7. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is -1322.18.
Currently, EBITDA for the company is -13.12 million with net debt to EBITDA at 7.71. When we switch over and look at the enterprise to sales, we see a ratio of 224.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.35.
Conclusion
To wrap up, the performance of BiomX Inc (PHGE) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
